1

2

This presentation contains forward-looking statements within the meaning of the Private Securities litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are considered forward-looking statements, which are usually identified by the use of words such as “anticipates,” believes,” “continues,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “ projects,” “seeks,” “should,” “will,” “forecast,” “budget,” and variations of such words or similar expressions. Statements of past performance, efforts or results, about which inferences or assumptions may be made, can also be forward-looking statements and are not indicative of future performance or results. Forward-looking statements are neither forecasts, promises nor guarantees, and are based on the current beliefs of the RxSight, Inc. (“RxSight,” “we” or “us”) management as well as assumptions made by and information currently available to RxSight. Such statements reflect the current views of RxSight with respect to future events and are subject to known and unknown risks, including business, regulatory, economic and competitive risks, uncertainties, contingencies and assumptions about RxSight, including, without limitation, (i) projections regarding future volume of cataract surgical procedures and the role of premium IOLs therein, (ii) estimates of RxSight’s addressable market opportunity, in the U.S. and globally, (iii) the efficacy of RxSight’s mechanisms and procedures, (iv) the performance of other premium and conventional IOLs compared to RxSight’s, (v) the number of patients eligible for LAL procedures, (vi) revenues associated with LAL procedures and the premium IOL market, (vii) statements regarding our future financial or business performance, (viii) the timing and success of our development and commercialization of our products, (ix) the continued acceptance of our products in the marketplace and (x) the impact of COVID-19, including currently known and unknown variants, on the premium IOL market, RxSight’s business and the demand for our products.

Certain information contained in this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and RxSight’s own internal estimates and research. While we believe these third-party sources to be reliable as of the date of this presentation, they have not been independently verified, and we make no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, all of the market data included in this presentation involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy for reliability of such assumptions. Finally, while we believe our own internal estimates and research are reliable, such estimates and research have not been verified by any independent source.

More details about these and other risks that may impact RxSight’s business are described under the heading “Risk Factors” in RxSight’s prospectus filed with the U.S. Securities and Exchange Commission (“SEC”) on July 29, 2021 and in subsequent filings with the SEC, which are available on the SEC’s website at www.sec.gov. RxSight cautions you not to place undue reliance on any forward-looking statement, which speaks only as of the date hereof. RxSight does not undertake any duty to update any forward-looking statement or other information in this presentation, except to the extent required by law.

3

*see slide 8

Acquired by Bausch & Lomb 1997 IPO 2004, Acquired by AMO 2007 Acquired by Bausch & Lomb 2008 Acquired by Alcon 2010

4

Development and Launch of LASIK, All Laser LASIK, Premium IOLs & Laser Cataract Surgery Markets

4

Management Team Board of Directors*

* Ron Kurtz also serves on BOD

51. Hashemi, H., et al. (2020). Global and regional prevalence of age-related cataract: a comprehensive systematic review and meta-analysis. Eye. doi:10.1038/s41433-020-0806-32. Market Scope 2020 IOL Report, May 2020 3. Market Scope 2021 IOL Report, April 2021

Natural Lens Removal Replacement with intraocular lens (IOL)

IOL

Conventional IOL replaces onlyspherical power of removed natural lens

Premium IOLs designed to reduce astigmatism and/or presbyopia

6

Eye Sphere Astigmatism Presbyopia

Right -2.00

Left -2.50

Eye Sphere Astigmatism Presbyopia

Right -2.00 -1.25 030 + 2.00

Left -2.50 -1.75 105 +2.00

1. Berdahl J. Clinical Ophthalmology 2020; 14: 3439–34502. Market Scope 2021 IOL Report, April 2021

Presbyopia affects nearly 100% of cataract surgery patients1

Nearly all patients need glasses for best vision after surgery

Potential for less dependence on glasses after surgery

Standard reimbursement of ~$500, plus additional payment from patient, an

extra $1500-$65002

Astigmatism affects >70% of cataract surgery patients

Example prescription for sphere only Example prescription for sphere, astigmatism and presbyopia

Global US

7

26.919.9

32.6

2.72.4

4.8 29.6

22.3

37.4

2019 2020 2026

3.8 3.1 4.4

0.7 0.6

1.2 4.4 3.7

5.5

2019 2020 2026

ConventionalPremium

1. Market Scope 2021 IOL Report, April 2021

8

19.9

2.4 22.3

2020 Procedures

3.1

0.6 3.7

2020 Procedures

1. Market Scope 2021 IOL Report, April 20212. Average selling price (or “ASP”) for the quarter ended 03/31/213. Calculation of total addressable market based on projected volumes multiplied by the RxLAL ASP for the quarter ended 03/31/21

Grow share in Premium

ConvertConventional

Procedures1 2.4 M 19.9 M

RxLAL ASP2 $976 $976

RxSightaddressable market opportunity3

$2.3 B $19.4 B

Current revenue in market1 $1.4 B $2.3 B

Our addressable opportunity

Conventional Premium

Our addressable opportunity

Conventional Premium

Grow share in Premium

ConvertConventional

Procedures1 0.6M 3.1M

RxLAL ASP2 $976 $976

RxSightaddressable market opportunity3

$0.6 B $3.0 B

Current revenue in market1 $0.4 B $0.4 B

Global (2020) U.S. (2020)

Choose Optics of IOL Before Surgery

Predict Powers of IOL Before Surgery

Manage Dissatisfaction AfterSurgery

9

Increasing Range Of Vision Decreases Quality Of Vision

Distance

Distance/Intermediate

Sphere

Astigmatism

Anisometropia

Residual Refractive

Error

Reduced Contrast Vision

Secondary Surgical

Procedure

Distance/Intermediate/Near

High Quality

Medium Quality

Lower Quality

Leaves patients and doctors with difficult pre-op decisions and post-op consequences

Choose MonofocalOptic & Power IOL Before Surgery

Optimize Vision with Light Treatments After Surgery

Patient Verifies Satisfaction AfterLight Treatments

10

1.0 0.5 0.0 -0.5 -1.0 -1.5 -2.0 -2.5 -3.0

Defocus (D)

+0.5

+0.4

+0.3

+0.2

+0.1

0.0

-0.1

Visu

al A

cuity

(Log

mar

)

Near Add = 1.25 D

Distant Eye

Near Eye

Standard Postoperative

Refraction

Light Treatment to Modify LAL

Light Adjustable

Lens

No Reduction

in Contrast3

Broadened & Elevated

Defocus Curve1,2

Adjustable Anisometropia

Titrate Vision in Both Eyes4

2 4 6 8 10 12 14 16 18 20

Cycles Per Degree

0

0.25

0.5

0.75

1

1.25

1.5

1.75

2

Mes

opic

Con

trast

Sen

sitiv

ity (l

og u

nits

)

LAL

Monofocal Control

1. RxSight Data on File.2. Chayet, A. Single Center Study (Data on File).3. RxSight P160055: FDA Summary of Safety and Effectiveness Data.

4. Newsome, AAO 2021 presentation on file.

Simplifies pre-op decisions and empowers patients and doctors post-op

11

Light Treatment After LAL

Implantation

1. Sandoval HP, Donnenfeld ED, Kohnen T, et al. Modern laser in situ keratomileusis outcomes. J Cataract Refract Surg. 2016;42(8):1224-1234.2. RxSight P160055: FDA Summary of Safety and Effectiveness Data.3. Monofocal (P040020/S087) . FDA Summary of Safety and Effectiveness Data.

Each EyeSeparately

•

•

•

•

12

0%

10%

20%

30%

40%

50%

60%

70%

80%

RxSight LAL Acrysof Tecnis

RxSight LAL Acrysof Tecnis

~2X more eyes with >20/20 vision without glasses1-3

1. RxSight P160055: FDA Summary of Safety and Effectiveness Data.2. Tecnis® Toric PMA P980040/S039: FDA Summary of Safety and Effectiveness Data. 2013.3. AcrySof® Toric P930014/S15: FDA Summary of Safety and Effectiveness Data. 2011.

0.00%

2.00%

4.00%

6.00%

8.00%

10.00%

12.00%

14.00%

16.00%

18.00%

RxSight LAL Acrysof Tecnis

RxSight LAL Acrysof Tecnis

~6x fewereyes with <20/32 vision without glasses1-3

Both Eyes Together

•

•

•

•

131. RxSight Data on File2. Chayet, A. Single Center Study (Data on File)3. RxSight P160055: FDA Summary of Safety and Effectiveness Data

4. Newsome, AAO 2021 presentation on file5. Panoptix SSED (P040020/S087)

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

LAL Series 1(n=17)

LAL Series 2(n=86)

Panoptix(n=129)

IntermediateNear

DistanceIntermediate

Broadened Depth of Focus

DISTANCE DISTANCEBroadened Depth of Focus

~2x moreeyes with >20/20 vision without glassesat all distances4,5

Each LAL case projected to increased net revenue by $1,2304

LDD to be “paid off” after a mean of 17 months5

Average net revenue increase of $89,000 per year5

Each LAL case increased net revenue by average of $16232

LDD was “paid off” after a mean of 5 months3

Average net revenue increase of $360,000 per year3

“Average” Premium Cataract Surgery Practice2Surveyed Practice Results1

14

RxSight Economic Impact Study by Haffey & Company

1. Survey of 15 RxSight customers installed for 4 to 23 months2. Based on practice estimated conversion of monofocal, toric and

presbyopia correcting IOLs and 125,000 LDD purchase price

3. Based on average of 16 LALs implanted per month in practices with ≥.6 months commercial history 4. Based on average pricing of monofocal, toric and presbyopia correcting IOLs as reported by MarketScope 2021 IOL report5. Based on average 6 implants per month (3 bilateral patients) and $125,000 LDD purchase price

Monofocal IOL Toric IOL

Presbyopia correcting

IOL

30% 34% 36%

Average estimate of percentage (%) of LAL procedures that

otherwise would have received:

Nearly every patient can be upgraded to LAL

•

•

•

•

•

15 1. Market Scope 2021 IOL Report, April 2021

Light Delivery Device (LDD)• Sold to Practice for ~$125,000

• Financing Programs from $1000 to $2800/month

Light Adjustable Lens (LAL)• Like all Premium IOLs, LAL

consigned to ASC

• $1000 billed at time of use

“Never before have I been so confident in my ability to deliver customized, precise vision outcomes to my patients.”Horizon Eye Specialists, Phoenix, AZ

16

Clinical Training Specialists

Field Service Engineers

Regional Sales

Director

Customer Support Manager

LAL Account Managers

0.0%

0.0%

2.9%

11.8%

85.3%

0% 20% 40% 60% 80% 100%

Strongly Disagree

Disagree

Not Sure

Agree

Strongly Agree

I would willingly recommend the RxSight Technology to a colleague, friend or family member1

97.1% Willingness to Recommend

“Why would you pick your lens, or buy your glasses, before surgery? The LAL has the best accuracy and the best quality of vision!”Slade & Baker Vision, Houston, TX

1. RxSight Customer Survey

17

U.S. Commercial Team Expansion

U.S. Regulatory Approvals of Technology Advances

International Expansion

Blocks UV except during LDD treatment

Opens during LDD treatment

18

*see slide 8

19